Страна: Канада
Язык: английский
Источник: Health Canada
SALMETEROL (SALMETEROL XINAFOATE)
GLAXOSMITHKLINE INC
R03AC12
SALMETEROL
50MCG
POWDER
SALMETEROL (SALMETEROL XINAFOATE) 50MCG
INHALATION
15X4 BLISTER DISKS
Prescription
SELECTIVE BETA 2-ADRENERGIC AGONISTS
Active ingredient group (AIG) number: 0126960002; AHFS:
CANCELLED POST MARKET
2017-09-20
_ _ _ _ _ _ _ _ _Page 1 of 50_ PRODUCT MONOGRAPH PR SEREVENT ® DISKHALER ® DISK salmeterol xinafoate dry powder for inhalation 50 mcg salmeterol (as the xinafoate salt)/blister PR SEREVENT ® DISKUS ® salmeterol xinafoate dry powder for inhalation 50 mcg salmeterol (as the xinafoate salt)/blister Bronchodilator (beta 2 -adrenergic stimulant) GlaxoSmithKline Inc. 7333 Mississauga Road Mississauga, Ontario L5N 6L4 www.gsk.ca Date of Revision: July 9, 2014 Submission Control No: 173662 _©_ _ 2014 GlaxoSmithKline Inc. All Rights Reserved_ _ _ _®_ _SEREVENT, DISKHALER and DISKUS are registered trademarks, used under license by GlaxoSmithKline Inc. _ _ _ _ _ _ _ _ _ _Page 2 of 50_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................11 DRUG INTERACTIONS ..................................................................................................17 DOSAGE AND ADMINISTRATION ..............................................................................19 OVERDOSAGE ................................................................................................................21 ACTION AND CLINICAL PHARMACOLOGY ............................................................22 STORAGE AND STABILITY ..........................................................................................23 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................24 PART II: SCIENTIFIC INFORMATION . Прочитать полный документ